Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Blue Water Ventures International Inc
(OP:
BWVI
)
0.0003
UNCHANGED
Last Price
Updated: 12:46 PM EDT, Oct 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Blue Water Ventures International Inc
Historical Regulatory Filing Deficiences Continue to Stifle Psycheceutical Biosciences
May 16, 2024
Via
ACCESSWIRE
Psycheceutical Bioscience Strategically Pivots Into the Brain-Computer Interface (BCI) Space
January 17, 2024
Via
ACCESSWIRE
Dr. Neilank Jha Appointed as Executive Chairman and Chief Executive Officer of Psycheceutical Bioscience Inc.
December 12, 2023
Via
ACCESSWIRE
Psycheceutical Bioscience Launches Wefunder Crowdfunding Campaign for Safer Psychedelic Dosing
November 01, 2023
Via
ACCESSWIRE
Psycheceutical Announces Successful First Cohort Dosing; Moves to Dose Escalation in Phase I Trial of NeuroDirect Ketamine for PTSD
August 10, 2023
Via
ACCESSWIRE
Psycheceutical Bioscience Announces Completion of PCAOB Audit and Future Corporation Action Strategy
August 01, 2023
Via
ACCESSWIRE
First Patient Dosed in Psycheceutical's Phase I Study Exploring Topical Administration of Ketamine to Treat PTSD
July 13, 2023
Via
ACCESSWIRE
The Next Generation Of Mental Health Treatment: Psycheceutical Bioscience Inc.’s (OTCPK:BWVI) Novel Topical Ketamine Delivery
April 18, 2023
Via
ACCESSWIRE
Psycheceutical Hosts MAPS Founder and Psychedelic Industry Leader Rick Doblin at Its Drug Development Lab
March 29, 2023
Doblin commented on the potential of the company’s NeuroDirect™ ketamine topical cream to help those suffering from PTSD
From
Psycheceutical Bioscience, Inc.
Via
GlobeNewswire
What If There Was A Topical Cream That Treated PTSD Without Side Effects? — Psycheceutical Bioscience, Inc (OTCPK: BWVI) Is Pioneering A Possible Solution
March 29, 2023
By Faith Ashmore, Benzinga
Via
TheNewswire.com
Psycheceutical Bioscience, Inc. Announces Observational Research Results for NeuroDirect™ Ketamine Topical Cream in Treating PTSD
March 21, 2023
From
Psycheceutical Bioscience, Inc.
Via
GlobeNewswire
Psycheceutical Bioscience, Inc (OTCPK: BWVI) Could Be Revolutionizing Psychedelic Health Care By Developing The First Ever Topical Psychedelic Cream To Treat PTSD
March 01, 2023
By Julian Richard, Benzinga
Via
TheNewswire.com
BioMedNewsBreaks – Psycheceutical Bioscience Inc. (BWVI) Inks Agreement for First-Ever Clinical Trials of a Proprietary Ketamine Topical Cream to Treat PTSD
February 17, 2023
Via
Investor Brand Network
Exposures
Product Safety
Psycheceutical to Conduct the First Ever Phase I and II Clinical Trials of a Novel Ketamine Topical Cream to Treat PTSD
February 15, 2023
From
Psycheceutical Bioscience, Inc.
Via
GlobeNewswire
Psycheceutical Announces Completion of Pre-IND Meeting with FDA for Topical Ketamine Drug to Treat PTSD
February 02, 2023
Company intends to pursue 505(b)(2) regulatory pathway for novel topical formulation of ketamine for the treatment of PTSD
From
Psycheceutical Bioscience, Inc.
Via
GlobeNewswire
Psycheceutical Bioscience Provisional Patent Application for Novel Ketamine Topical for the Treatment of PTSD
January 26, 2023
Topical ketamine formulations could improve the methods of treating post-traumatic stress disorder (PTSD)
From
Psycheceutical Bioscience, Inc.
Via
GlobeNewswire
Psycheceutical Announces Julian Bailes, M.D. as Board Member and Chief Medical Officer
January 10, 2023
Renowned neurosurgeon to oversee the development of breakthrough psychedelic therapeutics
From
Psycheceutical Bioscience, Inc.
Via
GlobeNewswire
Dr. Aric Logsdon Joins Psycheceutical Bioscience, Inc. as Company’s Scientific Director
November 29, 2022
Dr. Logsdon’s expertise to help guide the company’s further research and development for its patented drug-delivery technology
From
Psycheceutical Bioscience, Inc.
Via
GlobeNewswire
Psycheceutical Bioscience, Inc. Announces Medical Advisory Board
October 18, 2022
To be led by accomplished Neurosurgeon Dr. Julian Bailes, the Medical Advisory Board will support the Company in developing breakthrough psychedelic medicine technologies for mental health treatments
From
Psycheceutical Bioscience, Inc.
Via
GlobeNewswire
Psycheceutical Bioscience, Inc.'s Zappy Zapolin Added to The Benzinga Psychedelics Advisory Council
October 04, 2022
Chief Visionary Officer of Psycheceutical, Zappy Zapolin, will join other prominent leaders in Psychedelics on Benzinga’s Council Board
From
Psycheceutical Bioscience, Inc.
Via
GlobeNewswire
Psycheceutical Completes Acquisition by Blue Water Ventures International
January 20, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Blue Water Ventures International, Inc. Signs Non-Binding Letter of Intent to Acquire Psycheceutical, Inc.
November 03, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Blue Water Ventures International and Partners Endurance Exploration Group Share Update on the Current 2021 Recovery Season of Steamboat Pulaski
August 25, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
New Sonar Survey Discovers Large Unsalvaged Sections of SB Pulaski, 1838
June 23, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.